Prostatype Genomics AB Cash Flow Statement

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	-44.5	-41.05	-41.44	-29.09	-15.63
Other Adjustments	7.72	0.92	2.47	1.9	0.09
Change in Receivables	0.26	-0.24	0.98	-1.42	0.13
Changes in Inventories	0.02	0.11	-0.02	0	0.21
Changes in Accounts Payable	12.7	-4.44	8.86	0.91	-0.88
Operating Cash Flow	-23.8	-44.71	-29.14	-27.69	-16.08
Operating Cash Flow Growth	-	-	-	-	-
Capital Expenditures	-0.26	-0.29	-0.08	-	-
Purchases of Intangible Assets	-13.18	-7.58	-8.49	-	-2.5
Other Investing Activities	0.08	-0.49	-0	-	-
Investing Cash Flow	-13.36	-8.36	-8.57	-	-2.5
Long-Term Debt Issued	10.55	8.83	16.2	-	-
Long-Term Debt Repaid	-5.32	-15.23	-5.4	-0.4	-0.2
Net Long-Term Debt Issued (Repaid)	5.23	-6.4	10.8	-0.4	-0.2
Issuance of Common Stock	31.6	66.15	18.11	19.25	23.25
Net Common Stock Issued (Repurchased)	31.6	66.15	18.11	19.25	23.25
Financing Cash Flow	36.83	59.75	28.91	18.85	23.05
Foreign Exchange Rate Adjustments	-0.02	0.05	-0.01	-	-
Net Cash Flow	-0.33	6.69	-8.79	-8.84	4.47
Free Cash Flow	-24.06	-44.99	-29.21	-27.69	-16.08
Free Cash Flow Growth	-	-	-	-	-
FCF Margin	-4029.98%	-2268.99%	-771.40%	-4054.61%	-637.56%
Free Cash Flow Per Share	-0.71	-1.33	-361.46	-1521.34	-1152.76
Levered Free Cash Flow	-26.81	-52.07	-21.87	-28.57	-16.49
Unlevered Free Cash Flow	-26.48	-45.47	-30.48	-27.78	-16.21